Christopher J. Darus

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

Kathleen N. Moore, Michael A. Bookman, Jalid Sehouli et al. · Journal of Clinical Oncology · 2021 · 376 citations · Full text

The Use of p16 in Enhancing the Histologic Classification of Uterine Smooth Muscle Tumors

Kristen A. Atkins, Nora Arronte, Christopher J. Darus et al. · The American Journal of Surgical Pathology · 2008 · 135 citations

Identification of growth hormone receptor (GHR) tyrosine residues required for GHR phosphorylation and JAK2 and STAT5 activation.

X Wang, Christopher J. Darus, Bixiong C. Xu et al. · Molecular Endocrinology · 1996 · 92 citations · Full text

Growth Hormone Receptor, Cellular Physiology, Signaling Pathway +18

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Ignace Vergote, Giovanni Scambia, David M. O’Malley et al. · The Lancet Oncology · 2019 · 85 citations · Full text

Advanced Ovarian Cancer, Medicine, Pharmacology +9

Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

Bradley J. Monk, Michael W. Sill, Joan L. Walker et al. · Journal of Clinical Oncology · 2016 · 69 citations · Full text